TY - JOUR
T1 - Deployment of convalescent plasma for the prevention and treatment of COVID-19
AU - Bloch, Evan M.
AU - Shoham, Shmuel
AU - Casadevall, Arturo
AU - Sachais, Bruce S.
AU - Shaz, Beth
AU - Winters, Jeffrey L.
AU - Van Buskirk, Camille
AU - Grossman, Brenda J.
AU - Joyner, Michael
AU - Henderson, Jeffrey P.
AU - Pekosz, Andrew
AU - Lau, Bryan
AU - Wesolowski, Amy
AU - Katz, Louis
AU - Shan, Hua
AU - Auwaerter, Paul G.
AU - Thomas, David
AU - Sullivan, David J.
AU - Paneth, Nigel
AU - Gehrie, Eric
AU - Spitalnik, Steven
AU - Hod, Eldad A.
AU - Pollack, Lewis
AU - Nicholson, Wayne T.
AU - Pirofski, Liise Anne
AU - Bailey, Jeffrey A.
AU - Tobian, Aaron A.R.
N1 - Publisher Copyright:
© 2020, American Society for Clinical Investigation.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scaleup is brought underway to mobilize this critical resource.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scaleup is brought underway to mobilize this critical resource.
UR - http://www.scopus.com/inward/record.url?scp=85085757209&partnerID=8YFLogxK
U2 - 10.1172/JCI138745
DO - 10.1172/JCI138745
M3 - Review article
C2 - 32254064
AN - SCOPUS:85085757209
SN - 0021-9738
VL - 130
SP - 2757
EP - 2765
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 6
ER -